Brainstorm Cell Therapeutics Inc Investor Call Transcript
Greetings, and welcome to the BrainStorm Cell Therapeutics call to provide an update on NurOwn. (Operator Instructions) As a reminder, this call is being recorded. And I would now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.
Thank you. Good morning and thank you everyone for joining us. Before handing it over to the company management today for prepared remarks, I'd like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance; statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS; the sufficiency of the company's existing capital resources for continuing operations in 2023 and beyond; the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn, and related clinical development programs; and the company's ability to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |